Barclays PLC Makes New Investment in Protara Therapeutics, Inc. (NASDAQ:TARA)

Barclays PLC purchased a new stake in shares of Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 93,239 shares of the company's stock, valued at approximately $492,000. Barclays PLC owned 0.45% of Protara Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bailard Inc. acquired a new stake in Protara Therapeutics during the fourth quarter valued at $157,000. Commonwealth Equity Services LLC grew its position in Protara Therapeutics by 90.4% during the fourth quarter. Commonwealth Equity Services LLC now owns 37,000 shares of the company's stock valued at $195,000 after buying an additional 17,572 shares during the period. ADAR1 Capital Management LLC acquired a new stake in Protara Therapeutics during the fourth quarter valued at $648,000. Geode Capital Management LLC grew its position in Protara Therapeutics by 21.0% during the third quarter. Geode Capital Management LLC now owns 170,040 shares of the company's stock valued at $311,000 after buying an additional 29,514 shares during the period. Finally, Oppenheimer & Co. Inc. grew its position in Protara Therapeutics by 12.4% during the fourth quarter. Oppenheimer & Co. Inc. now owns 201,426 shares of the company's stock valued at $1,064,000 after buying an additional 22,301 shares during the period. Institutional investors and hedge funds own 38.13% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on TARA. Lifesci Capital began coverage on shares of Protara Therapeutics in a report on Tuesday, March 11th. They set an "outperform" rating and a $22.00 price objective on the stock. Scotiabank began coverage on shares of Protara Therapeutics in a report on Wednesday, April 16th. They set a "sector outperform" rating and a $12.00 price objective on the stock. Cantor Fitzgerald began coverage on shares of Protara Therapeutics in a report on Friday, March 14th. They set an "overweight" rating on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and set a $23.00 price objective on shares of Protara Therapeutics in a report on Monday, April 28th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $20.40.

Insider Buying and Selling

In related news, insider Jacqueline Zummo sold 21,224 shares of the business's stock in a transaction dated Wednesday, March 26th. The shares were sold at an average price of $4.53, for a total transaction of $96,144.72. Following the transaction, the insider now directly owns 98,861 shares in the company, valued at approximately $447,840.33. The trade was a 17.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 8.40% of the stock is currently owned by company insiders.

Protara Therapeutics Price Performance

TARA traded up $0.03 on Monday, reaching $3.27. 283,471 shares of the company's stock were exchanged, compared to its average volume of 782,473. The stock has a market cap of $126.15 million, a PE ratio of -1.16 and a beta of 1.73. Protara Therapeutics, Inc. has a twelve month low of $1.60 and a twelve month high of $10.48. The stock's fifty day moving average price is $4.00 and its 200-day moving average price is $4.11.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.29) earnings per share for the quarter, topping analysts' consensus estimates of ($0.47) by $0.18. As a group, research analysts predict that Protara Therapeutics, Inc. will post -3.32 earnings per share for the current fiscal year.

Protara Therapeutics Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.